"Second Opinion" with Christina Farr, Ash Zenooz MD & Luba Greenwood JD
Christina Farr, Luba Greenwood, Ash Zenooz
39 episodes
4 months ago
If you’re obsessed with health-tech and life sciences, this is the podcast for you. Second Opinion doesn't hold back. Join Luba Greenwood, Christina Farr, and Ash Zenooz as they bring influential entrepreneurs, experts and investors into the ring for candid conversations at the frontlines of healthcare and digital health every week. Healthcare, health-tech and life sciences in particular, is hard to navigate even for the most seasoned professionals. Unpacking the latest technological, medical, and scientific advances, regulatory hurdles, global economic shifts, and industry and investment trends, requires a powerful combination of hosts like us.
We aim to sift through the noise and help you navigate what’s really going on in healthcare and how to spot the next win. This season, we’re tackling meaty topics like biosecurity, the latest in telemedicine, why patient acquisition is so hard, and the pros and cons of VC versus private equity in funding startups in the healthtech space.
Christina Farr is a former investigative journalist for CNBC — during her tenure as a reporter, she broke some big health-tech stories ranging from Amazon’s first moves into the sector to Apple’s secretive acquisitions. Now Christina is the author at Second Opinion, a newsletter with +20K subscribers. Joining Christina are co-hosts Luba Greenwood, JD — former CEO of Kojin Therapeutics and managing partner at Dana-Farber Cancer Institute — and Ash Zenooz, MD — former CEO of Commure and partner at Luxeda Holdings.
Second Opinion is is a part of the Turpentine podcast network. Learn more: turpentine.co
All content for "Second Opinion" with Christina Farr, Ash Zenooz MD & Luba Greenwood JD is the property of Christina Farr, Luba Greenwood, Ash Zenooz and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
If you’re obsessed with health-tech and life sciences, this is the podcast for you. Second Opinion doesn't hold back. Join Luba Greenwood, Christina Farr, and Ash Zenooz as they bring influential entrepreneurs, experts and investors into the ring for candid conversations at the frontlines of healthcare and digital health every week. Healthcare, health-tech and life sciences in particular, is hard to navigate even for the most seasoned professionals. Unpacking the latest technological, medical, and scientific advances, regulatory hurdles, global economic shifts, and industry and investment trends, requires a powerful combination of hosts like us.
We aim to sift through the noise and help you navigate what’s really going on in healthcare and how to spot the next win. This season, we’re tackling meaty topics like biosecurity, the latest in telemedicine, why patient acquisition is so hard, and the pros and cons of VC versus private equity in funding startups in the healthtech space.
Christina Farr is a former investigative journalist for CNBC — during her tenure as a reporter, she broke some big health-tech stories ranging from Amazon’s first moves into the sector to Apple’s secretive acquisitions. Now Christina is the author at Second Opinion, a newsletter with +20K subscribers. Joining Christina are co-hosts Luba Greenwood, JD — former CEO of Kojin Therapeutics and managing partner at Dana-Farber Cancer Institute — and Ash Zenooz, MD — former CEO of Commure and partner at Luxeda Holdings.
Second Opinion is is a part of the Turpentine podcast network. Learn more: turpentine.co
Let's talk about men's health: hormones, longevity, and cultural shifts, with Hone CEO Saad Alam
"Second Opinion" with Christina Farr, Ash Zenooz MD & Luba Greenwood JD
44 minutes
9 months ago
Let's talk about men's health: hormones, longevity, and cultural shifts, with Hone CEO Saad Alam
In this episode of Second Opinion, Christina Farr and Luba Greenwood discuss men's health with Saad Alam, co-founder and CEO of Hone Health. They cover the rapid cultural shift in attitudes toward men's wellness, Alam's personal journey with hormone imbalances, and the emerging trends in health treatments for men, including testosterone therapy and lifestyle changes.
—
📰 Be notified early when Turpentine drops new publication: https://www.turpentine.co/exclusiveaccess
🙏 Help shape our show by taking our quick listener survey at https://bit.ly/TurpentinePulse
—
SPONSOR:
👩⚕️ Hot flashes, insomnia, brain fog? You don't have to accept these as just another part of aging. Midi Health is the virtual care clinic for women navigating midlife hormonal transition, offering FDA-approved medications, supplements and lifestyle coaching - all covered by insurance. Visit https://www.joinmidi.com/ to book your virtual visit today.
—
RECOMMENDED PODCAST:
Check out Modern Relationships, where Erik Torenberg interviews tech power couples and leading thinkers to explore how ambitious people actually make partnerships work. Founders Fund's Delian Asparouhov and researcher Nadia Asparouhova kick off the series with an unfiltered conversation about their relationship evolution.
Apple: https://podcasts.apple.com/us/podcast/id1786227593
Spotify: https://open.spotify.com/show/5hJzs0gDg6lRT6r10mdpVg
YouTube: https://www.youtube.com/@ModernRelationshipsPod
—
LINKS:
Hone Health: https://honehealth.com/
Subscribe to Second Opinion Newsletter: https://secondopinion.media/
—
FOLLOW:
https://www.linkedin.com/in/saad-alam-a146b311/
https://www.linkedin.com/in/christinafarr/
https://www.linkedin.com/in/lubagreenwood/
https://www.linkedin.com/in/ashzenooz/
—
HIGHLIGHTS FROM THE EPISODE:
Saad Alam started Hone Health after personally experiencing dismissive medical care when seeking help for his hormone-related health issues at age 35.
Modern men have 26% less testosterone and 50% fewer sperm compared to men 30 years ago.
Hone's treatment approach starts with lifestyle fundamentals (sleep, hydration, stress, movement) before considering medication.
The company performs comprehensive testing of 50 biomarkers and requires double testing before prescribing treatment.
Men's health stigma has decreased significantly in the past 4-5 years, partly due to influencers normalizing hormone discussions.
Men are increasingly open to wellness treatments like contrast therapy and Botox, with male Botox being the fastest-growing category.
The average Hone patient is 39 years old, significantly younger than the national average testosterone user age of 52.
Men strongly prefer testosterone treatment over weight loss medications, with 80% rejecting weight loss prescriptions.
Urban living is associated with a 30-40% higher likelihood of hormone imbalance due to environmental contaminants.
Hone conducts 45-minute consultations to create a safe space for men to discuss their health concerns openly.
Treatment monitoring includes regular checks for estrogen-related side effects and red blood cell counts.
Environmental factors like plastics, phthalates, and PCBs can significantly disturb hormone production.
The top concerns for male patients are energy, muscles, and libido, while women prioritize brain fog, night sweats, and mood.
The standard starting dose for testosterone treatment is 50-75mg per week, far lower than the 1000-2000mg used by bodybuilders.
"Second Opinion" with Christina Farr, Ash Zenooz MD & Luba Greenwood JD
If you’re obsessed with health-tech and life sciences, this is the podcast for you. Second Opinion doesn't hold back. Join Luba Greenwood, Christina Farr, and Ash Zenooz as they bring influential entrepreneurs, experts and investors into the ring for candid conversations at the frontlines of healthcare and digital health every week. Healthcare, health-tech and life sciences in particular, is hard to navigate even for the most seasoned professionals. Unpacking the latest technological, medical, and scientific advances, regulatory hurdles, global economic shifts, and industry and investment trends, requires a powerful combination of hosts like us.
We aim to sift through the noise and help you navigate what’s really going on in healthcare and how to spot the next win. This season, we’re tackling meaty topics like biosecurity, the latest in telemedicine, why patient acquisition is so hard, and the pros and cons of VC versus private equity in funding startups in the healthtech space.
Christina Farr is a former investigative journalist for CNBC — during her tenure as a reporter, she broke some big health-tech stories ranging from Amazon’s first moves into the sector to Apple’s secretive acquisitions. Now Christina is the author at Second Opinion, a newsletter with +20K subscribers. Joining Christina are co-hosts Luba Greenwood, JD — former CEO of Kojin Therapeutics and managing partner at Dana-Farber Cancer Institute — and Ash Zenooz, MD — former CEO of Commure and partner at Luxeda Holdings.
Second Opinion is is a part of the Turpentine podcast network. Learn more: turpentine.co